The Mysteries of Lipoprotein(a) and Cardiovascular Disease Revisited

Journal of the American College of Cardiology

Volumn 55, Issue 19, 2010, Pages 2168-2170

  Kiechl, Stefan ^a   Willeit, Johann ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

apolipoprotein(a); biomarkers; cardiovascular disease; lipoprotein(a); meta analysis

Indexed keywords

APOLIPOPROTEIN A; ISOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

ANALYTIC METHOD; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COPY NUMBER VARIATION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; GENOTYPE; HEART INFARCTION; HUMAN; PARTICLE SIZE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOGENESIS;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN(A); PROTEIN ISOFORMS; RISK FACTORS;

EID: 77951625682     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.048     Document Type: Editorial

References (14)

1. Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 59 (1963) 369-382
2. Utermann G. The mysteries of lipoprotein(a). Science 246 (1989) 904-910
3. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., and Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301 (2009) 2331-2339
4. Ober C., Nord A.S., Thompson E.E., et al. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J Lipid Res 50 (2009) 798-806
5. Berglund L., and Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 24 (2004) 2219-2226
6. Boffa M.B., Marcovina S.M., and Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 37 (2004) 333-343
7. Tsimikas S., and Witztum J.L. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 19 (2008) 369-377
8. Hervio L., Chapman M.J., Thillet J., Loyau S., and Anglés-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?. Blood 82 (1993) 392-397
9. Kronenberg F., Kronenberg M.F., Kiechl S., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100 (1999) 1154-1160
10. Zambrelli E., Emanuele E., Marcheselli S., Montagna L., Geroldi D., and Micieli G. Apo(a) size in ischemic stroke: relation with subtype and severity on hospital admission. Neurology 64 (2005) 1366-1370
11. Tsimikas S., Kiechl S., Willeit J., et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47 (2006) 2219-2228
12. Erqou S., Thompson A., Di Angelantonio E., et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 55 (2010) 2160-2167
13. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009) 412-423
14. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27 (2007) 1788-1795